Lista de obras -

Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy

artículo científico publicado en 2012

Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies

artículo científico publicado en 2013

Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor

artículo científico publicado en 2006

Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months

artículo científico publicado en 2013

Bafetinib, a dual Bcr-Abl/Lyn tyrosine kinase inhibitor for the potential treatment of leukemia

artículo científico publicado en 2010

Biological and clinical features of trisomy 21 in adult patients with acute myeloid leukemia

artículo científico publicado en 2013

Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemic stem cells

artículo científico publicado en 2011

EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience

artículo científico publicado en 2012

Experimental therapeutics for patients with myeloproliferative neoplasias

artículo científico publicado en 2010

Granulocyte-colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemia

artículo científico publicado en 2004

HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia

artículo científico publicado en 2013

Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia

artículo científico publicado en 2004

Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience

artículo científico publicado en 2012

Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies

artículo científico publicado en 2011

Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes

artículo científico publicado en 2013

Modest activity of pomalidomide in patients with myelofibrosis and significant anemia

artículo científico publicado en 2013

New agents in the treatment of chronic myelogenous leukemia

artículo científico publicado en 2009

Nilotinib therapy in chronic myelogenous leukemia

artículo científico publicado en 2007

Novel approaches in the treatment of systemic mastocytosis

artículo científico publicado en 2006

Ocular granulocytic sarcoma: a case report and literature review of ocular extramedullary acute myeloid leukemia

artículo científico publicado en 2012

Outcome after failure of second generation tyrosine kinase inhibitors treatment as first-line therapy for patients with chronic myeloid leukemia

artículo científico publicado en 2013

Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experience

artículo científico publicado en 2013

Peripheral blood blast clearance is an independent prognostic factor for survival and response to acute myeloid leukemia induction chemotherapy

artículo científico publicado en 2016

Ponatinib in Philadelphia chromosome-positive leukemias.

artículo científico publicado en 2014

Prognostic implications of chromosome 17 abnormalities in the context of monosomal karyotype in patients with acute myeloid leukemia and complex cytogenetics

artículo científico publicado en 2014

Similar outcome of patients with chronic myeloid leukemia treated with imatinib in or out of clinical trials

artículo científico publicado en 2013

The achievement of a 3-month complete cytogenetic response to second-generation tyrosine kinase inhibitors predicts survival in patients with chronic phase chronic myeloid leukemia after imatinib failure

artículo científico publicado en 2013

The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors

artículo científico publicado en 2011

The clinical significance of achieving different levels of cytogenetic response in patients with chronic phase chronic myeloid leukemia after failure to front-line therapy: is complete cytogenetic response the only desirable endpoint?

artículo científico publicado en 2011

The economic burden of pleural effusions in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors

artículo científico

Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase

artículo científico publicado en 2013

Lista de obras de

Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy

Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies

Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor

Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months

Bafetinib, a dual Bcr-Abl/Lyn tyrosine kinase inhibitor for the potential treatment of leukemia

Biological and clinical features of trisomy 21 in adult patients with acute myeloid leukemia

Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemic stem cells

EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience

Experimental therapeutics for patients with myeloproliferative neoplasias

Granulocyte-colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemia

HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia

Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia

Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience

Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies

Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes

Modest activity of pomalidomide in patients with myelofibrosis and significant anemia

New agents in the treatment of chronic myelogenous leukemia

Nilotinib therapy in chronic myelogenous leukemia

Novel approaches in the treatment of systemic mastocytosis

Ocular granulocytic sarcoma: a case report and literature review of ocular extramedullary acute myeloid leukemia

Outcome after failure of second generation tyrosine kinase inhibitors treatment as first-line therapy for patients with chronic myeloid leukemia

Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experience

Peripheral blood blast clearance is an independent prognostic factor for survival and response to acute myeloid leukemia induction chemotherapy

Ponatinib in Philadelphia chromosome-positive leukemias.

Prognostic implications of chromosome 17 abnormalities in the context of monosomal karyotype in patients with acute myeloid leukemia and complex cytogenetics

Similar outcome of patients with chronic myeloid leukemia treated with imatinib in or out of clinical trials

The achievement of a 3-month complete cytogenetic response to second-generation tyrosine kinase inhibitors predicts survival in patients with chronic phase chronic myeloid leukemia after imatinib failure

The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors

The clinical significance of achieving different levels of cytogenetic response in patients with chronic phase chronic myeloid leukemia after failure to front-line therapy: is complete cytogenetic response the only desirable endpoint?

The economic burden of pleural effusions in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors

Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase